[go: up one dir, main page]

PL3233103T3 - Leczenie pęcherzycy - Google Patents

Leczenie pęcherzycy

Info

Publication number
PL3233103T3
PL3233103T3 PL15823107T PL15823107T PL3233103T3 PL 3233103 T3 PL3233103 T3 PL 3233103T3 PL 15823107 T PL15823107 T PL 15823107T PL 15823107 T PL15823107 T PL 15823107T PL 3233103 T3 PL3233103 T3 PL 3233103T3
Authority
PL
Poland
Prior art keywords
pemphigus
treatment
Prior art date
Application number
PL15823107T
Other languages
English (en)
Inventor
Steven GOURLAY
Original Assignee
Principia Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc. filed Critical Principia Biopharma Inc.
Publication of PL3233103T3 publication Critical patent/PL3233103T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15823107T 2014-12-18 2015-12-18 Leczenie pęcherzycy PL3233103T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093891P 2014-12-18 2014-12-18
EP15823107.6A EP3233103B1 (en) 2014-12-18 2015-12-18 Treatment of pemphigus
PCT/US2015/066868 WO2016100914A1 (en) 2014-12-18 2015-12-18 Treatment of pemphigus

Publications (1)

Publication Number Publication Date
PL3233103T3 true PL3233103T3 (pl) 2021-04-19

Family

ID=55080225

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15823107T PL3233103T3 (pl) 2014-12-18 2015-12-18 Leczenie pęcherzycy

Country Status (14)

Country Link
US (2) US10485797B2 (pl)
EP (1) EP3233103B1 (pl)
CN (1) CN107257686B (pl)
AU (2) AU2015364335B2 (pl)
CA (1) CA2970723C (pl)
EA (1) EA036269B1 (pl)
ES (1) ES2843323T3 (pl)
IL (1) IL252839B (pl)
MA (1) MA41197B1 (pl)
MX (1) MX381283B (pl)
PL (1) PL3233103T3 (pl)
PT (1) PT3233103T (pl)
SG (1) SG11201704808VA (pl)
WO (1) WO2016100914A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2892900T3 (pl) 2012-09-10 2018-02-28 Principia Biopharma Inc. Związki pyrazolopirymidonowe jako inhibitory kinazy
SMT201700160T1 (it) 2013-04-25 2017-05-08 Beigene Ltd Composti eterociclici fusi come inibitori di protein chinasi
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
MX390619B (es) 2016-06-29 2025-03-21 Principia Biopharma Inc Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
PT3500299T (pt) * 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
IL284690B (en) 2016-12-15 2022-07-01 Hoffmann La Roche Process for preparing btk inhibitors
CN108329274B (zh) * 2017-01-13 2021-09-03 正大天晴药业集团股份有限公司 布鲁顿酪氨酸激酶抑制剂
CN110461847B (zh) * 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
CN108727404B (zh) * 2017-04-14 2020-05-12 中国科学院上海药物研究所 噻吩并[3,2-d]嘧啶类化合物、其制备方法及用途
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20210113568A1 (en) * 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
MX2021003064A (es) * 2018-09-18 2021-05-27 Beijing Innocare Pharma Tech Co Ltd Formas cristalinas de 6-(1-acriloilpiperidin-4-il)-2-(4-fenoxifeni l)nicotinamida.
MX2021004965A (es) 2018-11-06 2021-06-15 Beijing Innocare Pharma Tech Co Ltd Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida.
CN109939223B (zh) * 2019-04-04 2020-04-07 中南大学湘雅二医院 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
BR112022005575A2 (pt) 2019-10-09 2022-06-21 Principia Biopharma Inc Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila
MX2022004427A (es) 2019-10-14 2022-07-12 Principia Biopharma Inc Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
US11583533B2 (en) * 2020-01-08 2023-02-21 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
KR20220130184A (ko) 2020-01-22 2022-09-26 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CN117279641A (zh) 2021-04-16 2023-12-22 普林斯匹亚生物制药公司 通过施用特定化合物治疗药物和疫苗诱导的免疫性血小板减少症的方法
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
CN120112294A (zh) 2022-10-31 2025-06-06 普林斯匹亚生物制药公司 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
WO2024124113A1 (en) 2022-12-09 2024-06-13 Principia Biopharma Inc. Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib
CN116849178A (zh) * 2023-06-26 2023-10-10 武汉大学中南医院 胎源性成年骨关节炎易感模型的构建方法、共性干预靶标及其应用
TW202515567A (zh) 2023-06-30 2025-04-16 美商普林斯匹亞生物製藥公司 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療兒童、青少年和成人持續性或慢性免疫血小板減少症的方法
WO2025019544A1 (en) 2023-07-17 2025-01-23 Kadmon Corporation, Llc Combination therapy comprising btk inhibitor and belumosudil
TW202535404A (zh) 2023-10-25 2025-09-16 美商普林斯匹亞生物製藥公司 使用ｂｔｋ抑制劑２－［（３ｒ）－３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療與異位性皮炎和／或結節性癢疹相關的搔癢
WO2025122747A1 (en) 2023-12-06 2025-06-12 Principia Biopharma Inc. Treatment of moderate-to-severe asthma by administering rilzabrutinib

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082819A (en) 1977-03-02 1978-04-04 The Standard Oil Company Rubber-modified acrylonitrile-vinyl ether-indene polymers
JPS5663950A (en) 1979-10-30 1981-05-30 Mitsubishi Chem Ind Ltd Cyclopropanecarboxylic ester
FR2535721A1 (fr) 1982-11-08 1984-05-11 Sanofi Sa Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
JPS623848A (ja) 1985-06-28 1987-01-09 Nippon Steel Corp 疲労強度のすぐれたスタツド付きフラツシユバツト溶接アンカ−チエ−ン
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2518353B2 (ja) 1988-06-09 1996-07-24 住友化学工業株式会社 シアノ酢酸アミド誘導体およびその製造中間体
CA2018801C (en) 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
JPH04177244A (ja) 1990-11-10 1992-06-24 Konica Corp ハロゲン化銀写真感光材料
CA2033447C (en) 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH05301838A (ja) 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
JPH0827090A (ja) 1994-05-13 1996-01-30 Sumitomo Chem Co Ltd シアノ酢酸アミド誘導体、その用途およびその製造中間体
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
CA2283529A1 (en) 1997-03-14 1998-09-24 Basf Aktiengesellschaft Cycloalkylalkanecarboxamides and the production and use thereof
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
IL125947A0 (en) 1997-09-17 1999-04-11 American Cyanamid Co 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
WO1999018938A1 (en) 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PT1212327E (pt) 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
JP3991812B2 (ja) 2001-12-11 2007-10-17 住友化学株式会社 エステル化合物およびその用途
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
GB0219024D0 (en) 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
EP1597256A1 (en) 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
ES2295930T3 (es) 2003-08-01 2008-04-16 Chugai Seiyaku Kabushiki Kaisha Compuestos de cianoamida utiles como inhibidores de malonil-coa descarboxilasa.
BRPI0414082A (pt) 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
WO2005023773A1 (en) 2003-09-04 2005-03-17 Pfizer Limited Process for the preparation of substituted aryl pyrazoles
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
KR100774625B1 (ko) 2003-09-25 2007-11-08 워너-램버트 캄파니 엘엘씨 치료제 베타 아미노산
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP4552456B2 (ja) 2004-02-27 2010-09-29 住友化学株式会社 エステル化合物およびその用途
US20070197510A1 (en) 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
US7807719B2 (en) 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
CA2581375A1 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006228525A1 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20080146643A1 (en) 2005-06-15 2008-06-19 Pfizer Limited Combination
AU2006257647A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasites
US20070149464A1 (en) 2005-06-15 2007-06-28 Pfizer Inc. Combination
US20080176865A1 (en) 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
GB0517205D0 (en) 2005-08-22 2005-09-28 Novartis Ag Organic compounds
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
US8338594B2 (en) 2005-12-02 2012-12-25 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
AU2006336506B2 (en) 2006-01-13 2012-06-28 Pharmacyclics Llc Inhibitors of tyrosine kinases and uses thereof
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US20100292229A1 (en) 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
PL2049500T3 (pl) 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
AU2007323335A1 (en) 2006-11-23 2008-05-29 Novartis Ag Pyrimidines and their use as CXCR2 receptor antagonists
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
GB2447933A (en) 2007-03-27 2008-10-01 Chemence Ltd Cyanoacrylate monomer for forming an adhesive polymer
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
PT2250172E (pt) 2008-02-25 2011-11-30 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
CN101939324B (zh) 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
JP5492194B2 (ja) 2008-05-13 2014-05-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
ES2376404T3 (es) 2008-05-22 2012-03-13 Amgen Inc. Heterociclos como inhibidores de proteínas cinasas.
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
MX2011001259A (es) 2008-08-01 2011-03-15 Biocryst Pharm Inc Derivados de piperidina como inhibidores jak3.
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2011031896A2 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX2012005678A (es) 2009-11-16 2012-09-07 Univ California Enhibidores de cinasas.
RU2012152352A (ru) 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK
AU2011260961B9 (en) 2010-05-31 2015-02-26 Ono Pharmaceutical Co., Ltd. Purinone derivative
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN101880243A (zh) 2010-06-04 2010-11-10 贵阳柏丝特化工有限公司 一种含氟氰拟除虫菊酯化合物及其合成方法与用途
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
US20130178483A1 (en) 2011-06-28 2013-07-11 Pharmacyclics, Inc. Methods and Compositions for Inhibition of Bone Resorption
PH12014500122A1 (en) 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2734523A1 (en) 2011-07-19 2014-05-28 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
EP3495368B1 (en) * 2011-07-19 2023-05-31 Merck Sharp & Dohme B.V. (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
US20160045503A1 (en) 2012-06-18 2016-02-18 Principia Biopharma Inc. Formulations containing reversible covalent compounds
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
PL2892900T3 (pl) 2012-09-10 2018-02-28 Principia Biopharma Inc. Związki pyrazolopirymidonowe jako inhibitory kinazy
WO2014068527A1 (en) 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
MA38183A1 (fr) 2012-11-15 2017-03-31 Pharmacyclics Inc Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
TWI542588B (zh) 2014-02-03 2016-07-21 卡迪拉保健有限公司 新穎雜環化合物
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
IL252913B (en) 2014-12-24 2022-06-01 Principia Biopharma Inc Dose of site-specific btk inhibitor
WO2016105582A1 (en) 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
SI3303334T1 (sl) 2015-06-03 2021-09-30 Principia Biopharma Inc. Zaviralci tirozin kinaz
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
MX390619B (es) 2016-06-29 2025-03-21 Principia Biopharma Inc Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo

Also Published As

Publication number Publication date
CA2970723A1 (en) 2016-06-23
MX2017007973A (es) 2018-02-09
AU2015364335B2 (en) 2020-11-26
BR112017013022A2 (pt) 2018-02-27
SG11201704808VA (en) 2017-07-28
US20200101059A1 (en) 2020-04-02
CA2970723C (en) 2023-09-05
EA201791243A1 (ru) 2017-12-29
US10946008B2 (en) 2021-03-16
PT3233103T (pt) 2021-01-18
IL252839B (en) 2021-03-25
AU2015364335A1 (en) 2017-07-20
WO2016100914A1 (en) 2016-06-23
ES2843323T3 (es) 2021-07-16
EP3233103B1 (en) 2020-10-14
AU2020264338A1 (en) 2020-12-03
CN107257686A (zh) 2017-10-17
MA41197B1 (fr) 2021-01-29
MX381283B (es) 2025-03-12
EA036269B1 (ru) 2020-10-21
US20180050027A1 (en) 2018-02-22
CN107257686B (zh) 2021-01-29
US10485797B2 (en) 2019-11-26
IL252839A0 (en) 2017-08-31
EP3233103A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL285003A (en) Treatment of episode disorders
IL248856A0 (en) New treatment
SG11201609652RA (en) Treatment of polybacterials infections
GB201410116D0 (en) Method of treatment
IL246880A0 (en) Tumor treatment
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201400241D0 (en) Treatment
GB201400239D0 (en) Treatment
GB201400235D0 (en) Treatment
GB201400240D0 (en) Treatment
GB201400238D0 (en) Treatment
GB201417719D0 (en) New treatment
GB201408384D0 (en) New treatment
PT3546585T (pt) Ácidos nucleicos compreendendo um intrão modificado para utilização no tratamento de hiperbilirrubinemia